<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01950871</url>
  </required_header>
  <id_info>
    <org_study_id>CR2P01127</org_study_id>
    <secondary_id>DRKS00005263</secondary_id>
    <nct_id>NCT01950871</nct_id>
  </id_info>
  <brief_title>Prostate Guided Biopsy Study Evaluating the Diagnostic Performance of Prostate HistoScanning</brief_title>
  <acronym>PHSTT-01</acronym>
  <official_title>Diagnostic Performance of Prostate HistoScanningTM (PHS) in Men at Risk of Prostate Cancer Scheduled for an Initial Prostate Biopsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Advanced Medical Diagnostics s.a.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Advanced Medical Diagnostics s.a.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the PHSTT-01 trial is to determine if prostate HistoScanning (HS)
      analysis can be used to improve the detection of clinically significant prostate cancer
      (PCa), and potentially reduce the burden and number of biopsies in routine clinical practice.
      Prostate HS is an ultrasound-based tissue characterization technology specifically developed
      to detect, visualize, and locate tissue suspected of harboring PCa. These suspicious tissues
      are displayed as red areas on an imaging monitor. Recently a new biopsy guidance tool has
      been developed that uses the results of the prostate HS analysis.

      The subjects that will participate in this study are all scheduled for a first biopsy of the
      prostate. They will initially be imaged using transrectal ultrasound (TRUS) to obtain data
      for prostate HS analysis. The results of HS analysis will be used later in the procedure.
      Subjects will then undergo a routine systematic 10- to 12-core biopsy procedure using TRUS.
      This will be followed by a TRUS-guided biopsy that uses the result of prostate HS analysis
      and new biopsy guidance tool.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PHSTT-01 is a multi-center, prospective clinical trial to evaluate the diagnostic performance
      of prostate HistoScanning (HS) analysis in men at risk of PCa that have been scheduled for a
      first prostate biopsy. The purpose of this study is to determine if prostate HS analysis can
      improve the detection of clinically significant PCa, and potentially reduce the burden and
      number of biopsies in routine clinical practice. Subjects are men with serum total
      prostate-specific antigen (PCA) &lt;= 20ng/mL (&lt;= 10ng/mL if taking the 5-alpha reductase
      inhibitor).

      In a single visit, subjects will first be imaged with TRUS for the purpose of generating data
      for prostate HS analysis. The results of HS analysis will be used later in the procedure.
      Subjects will then undergo two consecutive biopsy procedures. First, using TRUS, a systematic
      10- to 12-core biopsy procedure will be performed. In turn, prostate HS data taken at the
      beginning of the procedure will be used to determine suspicious areas (displayed as red on an
      imaging monitor) and used to guide the biopsy procedure. Areas that are identified as
      suspicious (zero to a maximum of 3 areas) will then be sampled with two biopsy cores.
      Depending on the number of suspicious areas identified by prostate HS, the number of cores
      will be zero to a maximum of 6 cores.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Sponsor is bankrupt
  </why_stopped>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnostic performance of prostate HistoScanning (HS) to identify clinically significant PCa using histology outcomes from systematic prostate biopsy (Bx) as reference</measure>
    <time_frame>1 year</time_frame>
    <description>Compare prostate HS results to the systematic Bx outcome (positive or negative) for clinically significant PCa (defined as Gleason sum ≥ 7) in the non-run-in population.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Diagnostic performance of prostate HS to identify PCa using histology outcomes from systematic Bx as reference</measure>
    <time_frame>1 year</time_frame>
    <description>Compare prostate HS results to the systematic Bx outcome (positive or negative) for all PCa in the non-run-in population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diagnostic performance of prostate HS to identify clinically significant PCa using a combination of outcomes of both systematic Bx and HS-guided biopsy histology as reference</measure>
    <time_frame>1 year</time_frame>
    <description>Compare prostate HS results to the combination of systematic and HS-guided Bx outcomes (positive or negative) for clinically significant PCa (defined as Gleason sum ≥ 7) in the non-run-in population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in detection rates of clinically significant PCa between systematic and HS-guided biopsy.</measure>
    <time_frame>1 year</time_frame>
    <description>Compared PCa detection rates of systematic and HS-guided prostate Bx in the non-run-in population.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>single arm study</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Prostate HistoScanning (HS) analysis with HS-guided biopsy will be used to sample two cores per suspicious area (displayed as red on an imaging monitor), up to a maximum of 3 suspicious areas per subject. Depending on the number of suspicious areas identified by prostate HS, the number of cores will be zero (if no suspicious area is identified) up to a maximum of 6 cores.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Prostate HistoScanning</intervention_name>
    <description>In a single visit, subjects will first be imaged with TRUS for the purpose of generating data for prostate HS analysis. The results of HS analysis will be used later in the procedure. Subjects will then undergo two consecutive biopsy procedures. First, using TRUS, a systematic 10- to 12-core biopsy procedure will be performed. In turn, prostate HS data taken at the beginning of the procedure will be used to determine suspicious areas (displayed as red on an imaging monitor) and used to guide the biopsy procedure. Areas that are identified as suspicious (zero to a maximum of 3 areas) will then be sampled with two biopsy cores. Depending on the number of suspicious areas identified by prostate HS, the number of cores will be zero to a maximum of 6 cores.</description>
    <arm_group_label>single arm study</arm_group_label>
    <other_name>PHS/PHS TT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men at risk of PCa scheduled for first biopsy with serum total PSA

             ≤ 20 ng/ml (≤ 10 ng/mL if taking 5-alpha reductase inhibitors) from maximally 3 months
             ago

          -  Signed informed consent

        Exclusion Criteria:

          -  Previous prostate biopsy

          -  Confirmed PCa

          -  PSA &gt; 20 ng/ml (or &gt; 10 ng/mL if taking 5-alpha reductase inhibitors)

          -  Active urinary tract infection

          -  Presence/history of any confirmed cancer

          -  Recent prostatic surgery (past 6 months)

          -  History of pelvic radiotherapy
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bertrand Tombal, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cliniques Universitaires Saint-Luc, Brussels, Belgium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Krankenhaus der Barmherzigen Brüder</name>
      <address>
        <city>Vienna</city>
        <zip>1020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center Hanuschkrankenhaus</name>
      <address>
        <city>Vienna</city>
        <zip>1140</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center Med.Landeskrankenhaus Vöcklabruck</name>
      <address>
        <city>Vöcklabruck</city>
        <zip>4840</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center Onze Lieve Vrouw Ziekenhuis OLVZ</name>
      <address>
        <city>Aalst</city>
        <zip>9300</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center UZ VUB</name>
      <address>
        <city>Brussels</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>• University Medical Center Cliniques Universitaires Saint Luc</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center St. Marina University Hospital</name>
      <address>
        <city>Varna</city>
        <zip>9010</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center Urologická klinika - Fakultní nemocnice</name>
      <address>
        <city>Olomouc</city>
        <zip>775 20</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Všeobecná fakultní nemocnice v Praze (VFN) a 1. -General University Hospital and First Faculty of Medicine Charles University</name>
      <address>
        <city>Praha</city>
        <zip>15006</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>• University Medical Center Urinary Tract Surgery - Urology Dpt - Odense Universitetshospital Svendborg Sygehus</name>
      <address>
        <city>Odense C</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center North-Estonian Medical Center Foundation</name>
      <address>
        <city>Tallinn</city>
        <zip>13419</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center Institut Mutualiste Montouris</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center CHU Saint Etienne</name>
      <address>
        <city>Saint Etienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center Cancer Center - Prostatazentrum</name>
      <address>
        <city>Braunschweig</city>
        <zip>38126</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center Paracelsus Klinik</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40474</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center Martini Klinik - Prostate Cancer Center</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center Klinikum Herford</name>
      <address>
        <city>Herford</city>
        <zip>32049</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center PAN Klinik</name>
      <address>
        <city>Köln</city>
        <zip>50667</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center St. Elisabeth Krankenhaus</name>
      <address>
        <city>Leipzig</city>
        <zip>04277</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center Klinikum Leverkusen</name>
      <address>
        <city>Leverkusen</city>
        <zip>51375</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center Klinikum Wolfsburg Urologie</name>
      <address>
        <city>Wolfsburg</city>
        <zip>38440</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center Uro-Clin Ltd</name>
      <address>
        <city>Pécs</city>
        <zip>7601 Pf. 246</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center University Vita-Salute, Scientific Institute H. San Raffaele</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center URO</name>
      <address>
        <city>Riga</city>
        <zip>1006</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Vilniaus Universiteto Onkologijos Institutas - Santariškiu Clinics</name>
      <address>
        <city>Vilnius</city>
        <zip>08406</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center Antoni Van Leeuwenhoek Ziekenhuis - Nederlands Kanker Instituut</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Moscow State University of Medicine and Dentistry named after A.I.Evdokimov</name>
      <address>
        <city>Moscow</city>
        <zip>127473</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Vall d'Hebron University Hospital - Autonoma Universitat Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carouge medical centre</name>
      <address>
        <city>Carouge</city>
        <zip>1227</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center URO-TIP Urological Diagnosis Center</name>
      <address>
        <city>Istanbul</city>
        <zip>34740</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center Acıbadem Kozyatağı Hospital</name>
      <address>
        <city>Istanbul</city>
        <zip>34742</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center Blackpool Victoria Hospital</name>
      <address>
        <city>Blackpool</city>
        <zip>FY38NR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Nuffield Health - University Hospitals Bristol (UHB) - Bristol Royal Infirmary and Southmead Hospitals</name>
      <address>
        <city>Bristol</city>
        <zip>BS28HW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center Spire Washington Hospital</name>
      <address>
        <city>Tyne and Wear</city>
        <zip>NE38 9JZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>Czech Republic</country>
    <country>Denmark</country>
    <country>Estonia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>Netherlands</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://drks-neu.uniklinik-freiburg.de/drks_web/</url>
    <description>Deutsche Register für klinische Studien (DRKS)</description>
  </link>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 19, 2013</study_first_submitted>
  <study_first_submitted_qc>September 25, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 26, 2013</study_first_posted>
  <last_update_submitted>January 2, 2015</last_update_submitted>
  <last_update_submitted_qc>January 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 5, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HistoScanning</keyword>
  <keyword>TRUS</keyword>
  <keyword>Prostate cancer</keyword>
  <keyword>Biopsy guidance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

